Our Customers.

MVT in Silico collaborates with a diverse community of organizations advancing biomedical discovery and therapeutic development. Our computational modeling and simulation technologies are designed to support decision-making across the drug development lifecycle, from early research to translational and clinical investigation. We work with partners who seek scientifically rigorous and predictive computational tools to accelerate innovation while reducing experimental uncertainty.

Pharmaceutical and Biotechnology Companies

Pharmaceutical and biotechnology companies represent a central group of collaborators for MVT in Silico. These organizations rely on advanced modeling and simulation to better understand biological mechanisms, predict drug behavior, and optimize development strategies before entering costly experimental or clinical stages.

Our platforms are designed to assist research and development teams in exploring physiological responses, evaluating therapeutic hypotheses, and supporting model-informed drug development strategies. Across the industry, biosimulation technologies are widely used by pharmaceutical companies to guide dose selection, predict pharmacokinetic and pharmacodynamic behavior, and inform clinical trial design.

Through collaboration with biotechnology innovators and emerging therapeutic developers, MVT in Silico aims to support the translation of novel scientific ideas into viable therapeutic strategies.

Academic and Research Institutions

Academic laboratories and research institutes are essential partners in advancing the scientific foundations of computational biology. MVT in Silico works with academic investigators who seek advanced computational frameworks to study complex physiological systems, explore disease mechanisms, and test biological hypotheses through simulation.

Our modeling technologies enable researchers to investigate interactions across molecular, cellular, and physiological scales. By combining computational approaches with experimental insights, academic collaborators can generate new knowledge while improving the predictive power of biomedical research.

Contract Research Organizations and Translational Research Groups

Contract research organizations (CROs) and translational research groups increasingly integrate modeling and simulation into their service offerings. These organizations use predictive computational tools to support preclinical research, optimize study design, and interpret complex biological data.

MVT in Silico provides modeling frameworks that complement experimental workflows and enable partners to incorporate quantitative simulation into their research pipelines. This integrated approach helps organizations deliver more efficient and scientifically informed research programs.

Technology and Innovation Partners

Advances in digital biology depend on collaboration across computational science, life sciences, and data engineering. MVT in Silico engages with technology developers, software platforms, and data science organizations that contribute to the evolving ecosystem of digital biomedical research.

Through these partnerships, we aim to expand the capabilities of predictive modeling, integrate emerging computational techniques, and support the development of next-generation platforms for in silico experimentation.

Building Collaborative Scientific Partnerships

Our customers and collaborators share a commitment to advancing biomedical science through rigorous and responsible innovation. By combining mechanistic modeling, data-driven insights, and interdisciplinary expertise, MVT in Silico works with partners to enable more informed decisions in therapeutic research and development.

We welcome opportunities to collaborate with organizations interested in applying computational physiology, predictive simulation, and in silico experimentation to accelerate scientific discovery and improve the development of new therapies.